The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Adaptimmune; Forty Seven; Hylapharm; Loxo; Loxo (I); Zymeworks; Zymeworks (I)
Research Funding - Astellas Amgen BioPharama (Inst); Nektar (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); SQZ Biotech (Inst); Tolero Pharmaceuticals (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Consulting or Advisory Role - ABBVIE; AstraZeneca; Blueprint Medicines; BOEHRINGER INGELHEIM; BRISTOL-MYERS SQUIBB; Guardant Health; JANSSEN; LILLY; MERCK KGaA; MERCK SHARP & DOHME; NOVARTIS; PFIZER; Roche; SAMSUNG; TAKEDA
Speakers' Bureau - AstraZeneca; BRISTOL-MYERS SQUIBB; LILLY; MEDSCAPE; Merck Sharp & Dohme; NOVARTIS; PFIZER; prIME ONCOLOGY; ROCHE; TAKEDA; touchIME
Research Funding - Grant for Oncology Innovation; Merck
Other Relationship - GRÍFOLS
Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; CME Matters; Medscape; MJH Life Sciences; MLI Peerview; Prime Oncology; Research to Practice; Rockpointe
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Takeda
Research Funding - Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Farah Louise Lim
Honoraria - Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Gerson Lehrman Group; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Roche
 
Enriqueta Felip
No Relationships to Disclose
 
Ryan D. Gentzler
Honoraria - Rockpointe CME; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Helsinn Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst)
 
Shiven B. Patel
Research Funding - Merck (Inst); Takeda (Inst)
 
Joaquina Baranda
No Relationships to Disclose
 
Bruno Fang
Employment - NYU School of Medicine (I); Regional Cancer Care Associates
Leadership - Regional Cancer Care Associates
Stock and Other Ownership Interests - Regional Cancer Care Associates
 
Christian Michael Squillante
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Massive Bio
Research Funding - Exelixis (Inst)
 
Matteo Simonelli
Consulting or Advisory Role - Abbvie
 
Scott Werneke
Employment - Exelixis; Genentech
Stock and Other Ownership Interests - Exelixis; Genentech
Research Funding - Exelixis (Inst); Genentech
Travel, Accommodations, Expenses - Exelixis; Genentech
 
Dominic Curran
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Santiago Ponce Aix
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche
Travel, Accommodations, Expenses - AstraZeneca; Merck; Roche